Beta Drugs

The current share price of Beta Drugs Ltd (BETA) is ₹1,376.7. Today, the stock has gained by ₹139.60 (11.28%), trading in a range of ₹1,230 to ₹1,420. The stock opened at ₹1,247 with a trading volume of 82,141 shares.

Beta Drugs Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹0 crores, P/E ratio of 39.00, ROE of 25.90%, and ROCE of 27.00%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.

The 52-week high price of Beta Drugs Ltd (BETA) is ₹2,000, while the 52-week low is ₹990.1. Currently trading at ₹1,376.7, the stock is 38.3% away from its 52-week low and 31.2% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.

Whether to buy Beta Drugs Ltd stock at ₹1,376.7 depends on multiple factors. The stock is currently trading with a P/E ratio of 39.00 and P/B ratio of N/A. Today's performance shows a gain of 11.28%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.

Beta Drugs Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹1,376.7, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.

Beta Drugs Ltd's key financial metrics include: P/E Ratio: 39.00, P/B Ratio: N/A, ROE: 25.90%, ROCE: 27.00%, Dividend Yield: 0.00%, EPS: ₹41.50, Book Value: ₹219, Debt-to-Equity: 0.66, and Current Ratio: N/A. The company's market cap stands at ₹0 crores. These metrics help evaluate the company's valuation, profitability, and financial health.

Beta Drugs Ltd stock opened at ₹1,247 and is currently trading at ₹1,376.7, showing a gain of ₹139.60 (11.28%). The intraday high is ₹1,420 and low is ₹1,230. The trading volume stands at 82,141 shares, indicating moderate market participation today.

Beta Drugs Ltd has a Price-to-Earnings (P/E) ratio of 39.00, which means investors are willing to pay ₹39.00 for every ₹1 of earnings. With an EPS of ₹41.50, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.

Beta Drugs Ltd has a market capitalization of ₹0 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹1,376.7) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.

Beta Drugs Ltd has a book value of ₹219 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹1,376.7, which is 528.6% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.

Beta Drugs Ltd has a Return on Equity (ROE) of 25.90% and Return on Capital Employed (ROCE) of 27.00%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. Both metrics are strong, indicating efficient capital utilization. Higher percentages generally indicate better financial performance.

Beta Drugs Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.

Beta Drugs Ltd has a debt-to-equity ratio of 0.66, which measures the company's financial leverage by comparing total debt to shareholders' equity. This moderate ratio indicates balanced use of debt and equity. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.

Beta Drugs Ltd has an Earnings Per Share (EPS) of ₹41.50, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹1,376.7 and P/E ratio of 39.00, investors are paying 39.00 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.

Beta Drugs Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.

Beta Drugs Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.

To analyze Beta Drugs Ltd stock, consider: 1) Fundamental Analysis - Review P/E (39.00), ROE (25.90%), debt-to-equity (0.66), and growth rates. 2) Technical Analysis - Check 52-week range (₹990.10 - ₹2000.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹1376.70) with book value (₹219.00) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.

The face value (or par value) of Beta Drugs Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹1,376.7 is 13667x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.

Investing in Beta Drugs Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹990.10 - ₹2000.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.66 indicates leverage. 4) Liquidity Risk - Based on trading volume of 82,141 shares. 5) Valuation Risk - P/E of 39.00 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.

Beta Drugs Ltd operates in the industry with key metrics: P/E ratio of 39.00, ROE of 25.90%, market cap of ₹0 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.66), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.

Target prices for Beta Drugs Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹1,376.7, with a 52-week range of ₹990.10 to ₹2000.00. Based on fundamentals like P/E (39.00), ROE (25.90%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.

Consider selling Beta Drugs Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹1376.70. 2) Fundamental Deterioration - Declining ROE (currently 25.90%), increasing debt (D/E: 0.66), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.

Tax implications for Beta Drugs Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.